to other prescribers of opioids within such specialty and area. (III) Exclusions The Secretary may exclude the following individuals and prescribers from the analysis under this clause: (aa) Individuals receiving hospice services. (bb) Individuals with a cancer diagnosis. (cc) Prescribers who are the subject of an investigation by the Centers for Medicare & Medicaid Services or the Office of Inspector General of the Department of Health and Human Services. (iii) Contents of notification The Secretary shall, based on input from stakeholders, specify the resources and other information to be included in notifications provided under clause (i). (iv) Modifications and expansions (I) Frequency Beginning 5 years after the date of the enactment of this subparagraph, the Secretary may change the frequency of the notifications described in clause (i) based on stakeholder input. (II) Expansion to other prescriptions The Secretary may expand notifications under this subparagraph to include identifications and notifications with respect to concurrent prescriptions of covered Part D drugs used in combination with opioids that are considered to have adverse side effects when so used in such combination, as determined by the Secretary. (v) Opioids defined For purposes of this subparagraph, the term opioids has such meaning as specified by the Secretary through program instruction or otherwise. . 6066. No additional funds authorized No additional funds are authorized to be appropriated to carry out the requirements of this subtitle and the amendments made by this subtitle. Such requirements shall be carried out using amounts otherwise authorized to be appropriated. H Expanding Oversight of Opioid Prescribing and Payment 6071. Short title This subtitle may be cited as the Expanding Oversight of Opioid Prescribing and Payment Act of 2018 . 6072. Medicare Payment Advisory Commission report on opioid payment, adverse incentives, and data under the Medicare program Not later than March 15, 2019, the Medicare Payment Advisory